1-20 of 1652
azacitidine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Jong Bok Lee, Dilshad H. Khan, Rose Hurren, Mingjing Xu, Yoosu Na, Hyeonjeong Kang, Sara Mirali, Xiaoming Wang, Marcela Gronda, Yulia Jitkova, Neil MacLean, Andrea Arruda, Zoe Alaniz, Marina Y. Konopleva, Michael Andreeff, Mark D. Minden, Li Zhang, Aaron D. Schimmer
Journal: Blood
Blood (2021) 138 (3): 234–245.
https://doi.org/10.1182/blood.2020009081
Published: 2021
Includes: Supplemental data
Journal Articles

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Huthayfa Mujahed, Sophia Miliara, Anne Neddermeyer, Sofia Bengtzén, Christer Nilsson, Stefan Deneberg, Lina Cordeddu, Karl Ekwall, Andreas Lennartsson, Sören Lehmann
Journal: Blood
Blood (2020) 136 (3): 339–352.
https://doi.org/10.1182/blood.2019002326
Published: 2020
Includes: Supplemental data
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman
Journal: Blood
Blood (2019) 134 (Supplement_1): 829.
https://doi.org/10.1182/blood-2019-122896
Published: 2019
Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Mansour Alfayez, MDMS, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSc, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hussein Abbas, MD BS, Sreyashi Basu, PhD, Elias Jabbour, MD, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Koichi Takahashi, MD, Jing Ning, PhD, Steven M. Kornblau, MD, Koji Sasaki, MD, Lucia Masarova, MD, Wilmer Flores, James P Allison, PhD, Padmanee Sharma, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 830.
https://doi.org/10.1182/blood-2019-131494
Published: 2019
Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 832.
https://doi.org/10.1182/blood-2019-127345
Published: 2019
Journal Articles

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Courtney L Andersen, PhD, Amanda L Christie, MS, Alan Rosen, MS, Kim Maratea, DVM, PhD, Maureen Hattersley, Jon Travers, PhD, Justin Cidado, PhD, Sai Pulukuri, PhD, Jamal Saeh, PhD, Edwin Clark, PhD, Corinne Reimer, PhD, Jerome Mettetal, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1273.
https://doi.org/10.1182/blood-2019-129475
Published: 2019
Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1279.
https://doi.org/10.1182/blood-2019-130579
Published: 2019
Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Guillermo Garcia-Manero, MD, James McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Amer M. Zeidan, MBBS, MHS, Aref Al-Kali, MD, Kim-Hien Dao, DO, PhD, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD, Nancy Zhu, MD, Nashat Y. Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Aditi Shastri, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Aram Oganesian, PhD, Yong Hao, MD PhD, Harold N. Keer, MD PhD, Mohammad Azab, MD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 846.
https://doi.org/10.1182/blood-2019-122980
Published: 2019
Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 734.
https://doi.org/10.1182/blood-2019-128648
Published: 2019
Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 878.
https://doi.org/10.1182/blood-2019-126020
Published: 2019
Journal Articles

Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa E. Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 738.
https://doi.org/10.1182/blood-2019-128909
Published: 2019
Journal Articles

Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine

Courtney L Jones, PhD, Brett M. Stevens, PhD, Rachel Culp-Hill, BS, Angelo Dalessandro, PhD, Anna Krug, BS, Madeline Goosman, Shanshan Pei, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1272.
https://doi.org/10.1182/blood-2019-125773
Published: 2019
Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4748.
https://doi.org/10.1182/blood-2019-128821
Published: 2019
Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Toru Kiguchi, MD PhD, Shinya Sato, MD, Kensuke Usuki, MD PhD, Ken Ishiyama, Yoshikazu Ito, MD PhD, Takahiro Suzuki, MD PhD, Jun Taguchi, MD PhD, Shigeru Chiba, MD PhD, Nobuaki Dobashi, MD, Akihiro Tomita, MD PhD, Hironori Harada, MD PhD, Hiroshi Handa, MD PhD, Shigeo Horiike, MD PhD, Tomoya Maeda, MD PhD, Mitsuhiro Matsuda, MD PhD, Motoshi Ichikawa, MD, Tomoko Hata, MD, PhD, Sumihisa Honda, Satoshi Iyama, MD PhD, Hitoshi Suzushima, MD PhD, Yukiyoshi Moriuchi, MD, Toshiro Kurokawa, MD PhD, Takahiro Yamauchi, MD PhD, Hitoshi Kiyoi, MD PhD, Tomoki Naoe, MD PhD, Yasushi Miyazaki, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 845.
https://doi.org/10.1182/blood-2019-122802
Published: 2019
Journal Articles

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis

Lucia Masarova, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Maro Ohanian, DO, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Romany Gergis, Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1656.
https://doi.org/10.1182/blood-2019-130691
Published: 2019
Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Elias Jabbour, MD, Caleb Class, PhD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Zeev E. Estrov, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Yesid Alvarado, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Hui Yang, PhDMD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1715.
https://doi.org/10.1182/blood-2019-129141
Published: 2019
Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1718.
https://doi.org/10.1182/blood-2019-129129
Published: 2019
Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1720.
https://doi.org/10.1182/blood-2019-130155
Published: 2019
Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1721.
https://doi.org/10.1182/blood-2019-126426
Published: 2019